Therapeutic Effects of Combined Treatment with the AEA Hydrolysis Inhibitor PF04457845 and the Substrate Selective COX-2 Inhibitor LM4131 in the Mouse Model of Neuropathic Pain

Endocannabinoid and Prostanoid Crosstalk in Pain

(2019) Baptiste Buisseret et al.   TRENDS IN MOLECULAR MEDICINE

Detection of Cyclooxygenase-2-Derived Oxygenation Products of the Endogenous Cannabinoid 2-Arachidonoylglycerol in Mouse Brain

(2018) Amanda J. Morgan et al.   ACS Chemical Neuroscience

WWL70 protects against chronic constriction injury-induced neuropathic pain in mice by cannabinoid receptor-independent mechanisms

(2018) Jie Wen et al.   Journal of Neuroinflammation

Enhanced endocannabinoid tone as a potential target of pharmacotherapy

(2018) Marek Toczek et al.   LIFE SCIENCES

Therapeutic Effect of the Substrate-Selective COX-2 Inhibitor IMMA in the Animal Model of Chronic Constriction Injury

(2018) Melissa Jones et al.   Frontiers in Pharmacology

The cannabinoid system and pain

(2017) Stephen G. Woodhams et al.   NEUROPHARMACOLOGY

The Endogenous Cannabinoid System: A Budding Source of Targets for Treating Inflammatory and Neuropathic Pain

(2017) Giulia Donvito et al.   NEUROPSYCHOPHARMACOLOGY

Structure–activity relationships for the synthesis of selective cyclooxygenase 2 inhibitors: an overview (2009–2016)

(2017) G. Carullo et al.   MedChemComm

Interleukin-6: an emerging regulator of pathological pain

(2016) Ya-Qun Zhou et al.   Journal of Neuroinflammation

Pain regulation by non-neuronal cells and inflammation

(2016) R.-R. Ji et al.   SCIENCE

Cyclooxygenase-2 inhibition reduces stress-induced affective pathology

(2016) Joyonna Carrie Gamble-George et al.   eLife

Dual-Acting Compounds Targeting Endocannabinoid and Endovanilloid Systems—A Novel Treatment Option for Chronic Pain Management

(2016) Natalia Malek et al.   Frontiers in Pharmacology

ADouble Whammy: Targeting Both Fatty Acid Amide Hydrolase (FAAH) and Cyclooxygenase (COX) To Treat Pain and Inflammation

(2015) Rita Scarpelli et al.   ChemMedChem

R-flurbiprofen attenuates experimental autoimmune encephalomyelitis in mice

(2014) K. Schmitz et al.   EMBO Molecular Medicine

Combined inhibition of FAAH and COX produces enhanced anti-allodynic effects in mouse neuropathic and inflammatory pain models

(2014) Travis W. Grim et al.   PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR

Substrate-selective COX-2 inhibition as a novel strategy for therapeutic endocannabinoid augmentation

(2014) Daniel J. Hermanson et al.   TRENDS IN PHARMACOLOGICAL SCIENCES

Importance of glial activation in neuropathic pain

(2013) Joanna Mika et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Substrate-selective COX-2 inhibition decreases anxiety via endocannabinoid activation

(2013) Daniel J Hermanson et al.   NATURE NEUROSCIENCE

Inhibitors of endocannabinoid breakdown for pain: Not so FA(AH)cile, after all

(2012) Vincenzo Di Marzo   PAIN

An efficient randomised, placebo-controlled clinical trial with the irreversible fatty acid amide hydrolase-1 inhibitor PF-04457845, which modulates endocannabinoids but fails to induce effective analgesia in patients with pain due to osteoarthritis of the knee

(2012) John P. Huggins et al.   PAIN

Discovery of Prostamide F2α and Its Role in Inflammatory Pain and Dorsal Horn Nociceptive Neuron Hyperexcitability

(2012) Luisa Gatta et al.   PLoS One

The serine hydrolases MAGL, ABHD6 and ABHD12 as guardians of 2-arachidonoylglycerol signalling through cannabinoid receptors

(2011) J. R. Savinainen et al.   Acta Physiologica

Endocannabinoid Oxygenation by Cyclooxygenases, Lipoxygenases, and Cytochromes P450: Cross-Talk between the Eicosanoid and Endocannabinoid Signaling Pathways

(2011) Carol A. Rouzer et al.   CHEMICAL REVIEWS

Peripheral Nerve Injury Alters Blood-Spinal Cord Barrier Functional and Molecular Integrity through a Selective Inflammatory Pathway

(2011) S. Echeverry et al.   JOURNAL OF NEUROSCIENCE

Mechanistic and Pharmacological Characterization of PF-04457845: A Highly Potent and Selective Fatty Acid Amide Hydrolase Inhibitor That Reduces Inflammatory and Noninflammatory Pain

(2011) K. Ahn et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

(R)-Profens are substrate-selective inhibitors of endocannabinoid oxygenation by COX-2

(2011) Kelsey C Duggan et al.   Nature Chemical Biology

Biosynthesis and degradation of the endocannabinoid 2-arachidonoylglycerol

(2010) Natsuo Ueda et al.   BIOFACTORS

Chemokines, neuronal–glial interactions, and central processing of neuropathic pain

(2010) Yong-Jing Gao et al.   PHARMACOLOGY & THERAPEUTICS

R-Flurbiprofen Reduces Neuropathic Pain in Rodents by Restoring Endogenous Cannabinoids

(2010) Philipp Bishay et al.   PLoS One

The Role of Glia and the Immune System in the Development and Maintenance of Neuropathic Pain

(2010) Ricardo Vallejo et al.   Pain Practice

Inhibitors of Endocannabinoid-Metabolizing Enzymes Reduce Precipitated Withdrawal Responses in THC-Dependent Mice

(2009) Joel E. Schlosburg et al.   AAPS Journal

Emerging strategies for exploiting cannabinoid receptor agonists as medicines

(2009) Roger G Pertwee   BRITISH JOURNAL OF PHARMACOLOGY

Substance P Drives Endocannabinoid-Mediated Disinhibition in a Midbrain Descending Analgesic Pathway

(2009) G. M. Drew et al.   JOURNAL OF NEUROSCIENCE

Enhancement of endocannabinoid signaling by fatty acid amide hydrolase inhibition: A neuroprotective therapeutic modality

(2009) Jeannie Hwang et al.   LIFE SCIENCES

Dynamic Regulation of the Endocannabinoid System: Implications for Analgesia

(2009) Devi Rani Sagar et al.   Molecular Pain

The diverse CB1and CB2receptor pharmacology of three plant cannabinoids: Δ9-tetrahydrocannabinol, cannabidiol and Δ9-tetrahydrocannabivarin

(2007) R G Pertwee   BRITISH JOURNAL OF PHARMACOLOGY